Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here is the web site to help your spelling... and other issues you have.
https://www.anavex.com/
How, ath, would we know something? By what Anavex tells us, i.e., it achieved the endpoints in P2b/3 trial as noted in 12/22 PR and it has sufficient results to proceed with AA soon, noted in last week's PR. Not to mention, the indications that the peds' Rett trial will demonstrate efficacy with those young girls.
We know that, right ... now, all we need to do is wait for the Rett numbers and the expectant peer review paper on AD trial data.
Will one of the mods "stick" this?
Actually summarizes the two camps: No one knows "jack" when compared to what Anavex and TGD knows!
TIA
So ...
bas, raja nor anyone else would have known about "super responders" because Dr. Missling never called them that ... he called them "Strong Responders." TGD did not want the word "super" used due to its misinterpretation as to the results.
Only on MB's, is "super" used.
Still, unbelievable given the extent of content and your interpretation, writing and posting in 108 seconds.
P.S. Investor, saw your post re: tweet. That explains it!
So, Investor, do you get an advance notice of Anavex's PR? The PR was released at 7:29 AM, EDT, and your lengthy post was printed on 7:30:48, less than two minutes thereafter.
???
X, I am, too, but the Hopkins doctors claim his liver is shot and now their concern is help his kidneys to make him comfortable for his last few weeks. Also, dialysis is not happening.
Heard you have been on an upward trajectory. Glad to know.
Thanks, Hoskuld and Investor, for your concerns/empathy.
Believe what you want.
FYI - I'm off to daily Mass, but this time to pray for a family member with only weeks left as he suffers from an aggressive form of liver cancer, which was only discovered in late July.
My guess is that he has seen mucho more data than anyone on this MB has, including you and Doc.
His inclusion, Kb, is to increase credibility in those numbers as an expert in the field and one who will be able to speak the truth to others when the time comes. He is not there for more blarcamesine AD P3 trials as you insinuate.
Investor, I wouldn't call it nothing. As an authority in the field, he has seen the data, calls it "... robust clinical data ..." and, then, says "Yes!" to joining the SAB as its chairman. If he did not think it were good, he would not have signed-up.
mike, only if you and your handlers want it to go there!
mrp, I think he has seen the data; he states it is "... robust clinical data ..."
Thanks, hnbadger.
Has he spoken at this venue before? Do you think we'll receive news before the 13th?
Thanks, Doc. The next question is: will the Strong Responders' percentage be the same?
avxllent, thanks for your post. I thought that all weekend as those on the other side seemed very, very active this past weekend with posts continuing each day, all day long, even though it was a holiday weekend.
sokol, participants continue their SOC and added blarcamesine.
For both groups (30 and 50 mg), there were ~2 of out 3 taking DPZ, with the rest being DPZ-naive.
Tred, this is what I found:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517678/#:~:text=In%20AD%20dementia%2C%20the%20mean,050%20to%20%E2%88%92.
As to those over 60 who experience amyloid issues, I found this:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280058/
Tred, not sure if the blood test will have a correlation bias between 1) amyloid and 2) AD [if 1) = Y, then 2) is Y] or if the intent is to determine other biomarkers than amyloid that will predict Alzheimer's. I'll let the Board know what the results are in 4-6 weeks.
Steady, here is the AlzMatch Study/APT Web information on its blood draw, of which I had earlier in the week.
How can a blood test advance Alzheimer's research?
Tred, my thought is biomarkers are going to be examined and I'll learn what they indicate. My Mary is doing so, too.
Phase I trial results ... see link below.
https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-says-parkinsons-stem-cell-therapy-improves-symptoms-initial-trial-
2023-08-28/
Or, Investor, as you pointed out, Anavex might look at the 48-week data (which is ending now in mid/late August) of the OLE. With that data, there might be sufficient evidence that the OLE primary and secondary endpoints are being met and could be used for the AA, given that the OLE trial, if acceptable, does not need to be completed to be used in the AA decision.
IMO, the secondary endpoints will be where the "Strong Responders" carry the day.
You are correct it is funny, but we don't have an "x12" poster ... we have, however, a "12x" poster. ;)
george, do you know what "~" means?
If you do, then ~230,000 is acceptable!
abe, ~230,000 shares were retained by TGD.
bas, if Investor were correct with the highlighted phrase below, then the read-out s/b occurring now as 48 weeks from mid-September 2022 is ~ August 20th, 2023. If the read-out is done now, that might prove to be the trial needed for AA approval, given the un-stated desire by the fda to have such a trial in progress.
Pazzo, it is a 96 week OLE, which ends in July2024, therefore everyone had to have been enrolled by mid-September 2022. My take is that 450 is a solid number.
Please provide quote.
Jeffrey Cummings, an Anavex SAB member, is quoted.
https://www.biopharma-reporter.com/Article/2023/08/15/vaxxinity-alzheimer-s-treatment-shows-promising-results-in-early-trial
FYI - A webinar sponsored by Eisai on September 7th. I wonder if HH will present.
https://webinars.endpts.com/alzheimers-disease-using-deep-human-biology-learning-to-guide-next-generation-treatments/?source=Early-Edition
Sorry for the interlude, but I went to a funeral of a fellow Cursillista.
Pass on any further comments.
Then, you need to review the definition of "past".
I think you mean ...
The other word gives the impression that the approval opportunity was missed ... and I know you don't mean that.
Tred, it's what happens to a "fair" moderator.